Nippon Shinyaku

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Nippon Shinyaku's Japan sales performance.

FDA approves Sarepta rival NS Pharma’s Duchenne drug

Drug approved for patients with exon 53 mutation. Japanese pharma Nippon Shinyaku (NS Pharma) has scored US Food and Drug Administration (FDA) approval for its Duchenne muscular dystrophy drug viltolarsen, now

FDA sets Q3 decision date for NS Pharma’s DMD drug

NS Pharma and its parent company Nippon Shinyaku are currently enrolling patients for a phase 3 study in Japan and the US – named RACER53.

Wave’s challenge to Sarepta in Duchenne falls flat

The demise of Wave’s programmes leaves Japan’s Nippon Shinyaku Pharma as the main rival to Sarepta in DMD.

Solid Bio falls as FDA halts DMD trial over safety concerns

In the meantime, rival candidate viltolarsen from Japanese pharma Nippon Shinyaku (NS Pharma) has been filed with the FDA for the treatment of DMD.

Sarepta rival NS Pharma files Duchenne drug with FDA

Another blow for Sarepta following FDA rejection earlier this year. Japanese pharma Nippon Shinyaku (NS Pharma) has announced its candidate for Duchenne musuclar dystrophy (DMD) has been submitted to the FDA

1 2 3 4 [ Next 5 results ]

Data provided by GlobalData

GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com

For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology

COVID-19 Updates and Daily News

Surviving cancer: a new era for patients: Now more than ever, a shift in perspective is needed...
Crisis? No problem!: Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?: First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....